banda transcan 2 2016ul

Projects selected for funding under JTC 2015 on: "Immunology and immunotherapy of cancer: strengthening the translational aspects"

Impact of dietary intervention on tumor immunity
Dual epigenetic targeting and immunotherapy to fight against cancer
Mutated neo-antigens in hepatocellular carcinoma
Deciphering immune response against glioblastoma to find new targets
Targeting sphingolipid metabolism to improve anti-melanoma immunotherapy
Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical "proof-of-concept" to the development of phase Ib study
Prediction of nivolumab action in metastatic renal cancer patients:Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy




Projects funded under JTC 2014 (EC co-funded call) on: "Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy"

Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial
Patient‐derived models for intratumour functional heterogeneity and its implications for personalized medicine
Clinical impact of intratumor heterogeneity in metastatic breast cancer
Cancer evolution and identification of relapse-initiating cells
Defeating Recurrence and resistance in AML:Multigenomic Approaches to analyse heterogeneity
Fighting Resistance in CLL
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance
Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer
Evolution of resistant clones to novel target-directed drugs in colorectal tumors. A genetic and epigenetic study of intratumoral  heterogeneity dynamics
Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy
Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming   immunologically-induced dedifferentiation
Overcoming Neuroblastoma Tumour HETerogeneity, Resistance and RecurrAnCe
Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance
TArgeting Colon Tumor Initiating Cell heterogeneity
Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response
Targeting Of Resistance in PEDiatric Oncology



Projects funded under JTC 2013 on: "Translational research on tertiary prevention in cancer patients"

A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients
Exploiting the peptidome of atypical teratoid/rhabdoid tumors - characterization of novel tumor-associated antigens for immunotherapy in order to maintain long-term remissions
Biomarkers of tumor recurrence in pancreatic cancer
MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases
A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention
Biomarkers related to folate-dependent one-carbon metabolism in CRC recurrence and survival
Identification of genetic markers involved in development of metastases and second cancers in melanoma
High resolution project on prognosis and CARE of cancer patients
Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies
A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence 



Projects funded under JTC 2012 on: “Translational research on primary and secondary prevention of cancer”

An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology determinants
Cancer prevention through improved familial risk assessment and gene discovery
New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors
Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome
Metabolomic profiles throughout the continuum of colorectal cancer
Nanoparticle-Enhanced molecular Fluorescence-Endoscopy for detection of early-stage colorectal adenocarcinomas
Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin
Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers
TRanslational Implementation of Genetic Evidence in the management of MDS



Projects funded under JTC 2011 on: "Validation of biomarkers for personalised cancer medicine"

K-RAS mutations and DNA repair function in NSCLC
Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer
Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT
Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid carcinoma
Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia
Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer
PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine
Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice
CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer
Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patients


 3rd Joint Transnational Call for Research Proposals (JTC 2016)- Call closed on 13 February 2017

on: “Minimally and non-invasive methods for early detection and/or progression of cancer”

Visit the call page for further details:  JTC 2016

Projects selected for funding in the Second Joint Transnational Call for Proposals 2015
(JTC 2015)



Newsletter 3, September 2017

Newsletter 2, April 2017

Newsletter 1, December 2016


To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Cookie consent script